^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD70-targeted CAR-T immunotherapy

    Related drugs:
    15d
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (clinicaltrials.gov)
    P1, N=39, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD70 (CD70 Molecule)
    |
    8R-70CAR T
    20d
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, University of Florida | N=18 --> 24
    Enrollment change
    |
    8R-70CAR T
    1m
    IMPACT MET: IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Florida
    New P1 trial
    |
    8R-70CAR T
    2ms
    Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=15, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Trial primary completion date: Feb 2026 --> Mar 2027
    Trial primary completion date
    2ms
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CTX131
    3ms
    A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1 trial
    3ms
    CRISPR-Mediated Cancer Therapies: Approaches to Direct Tumor Targeting. (PubMed, Crit Rev Oncol Hematol)
    Clinical trials with CRISPR-engineered T-cells (e.g., CTX130) have demonstrated remission rates in hematologic malignancies. However, significant challenges remain, including cytokine release syndrome, immunotoxicity, tumor heterogeneity, and limited delivery efficiency in solid tumors. Overcoming these barriers requires interdisciplinary innovation, ethical oversight, and technological refinement to support the safe and effective integration of CRISPR-based strategies into precision oncology.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS G12D • KRAS G12
    |
    CTX130
    3ms
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    8R-70CAR T
    3ms
    IMPACT: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD70 (CD70 Molecule)
    |
    8R-70CAR T
    5ms
    Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    CD70 CAR-T
    6ms
    Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy. (PubMed, J Immunother Cancer)
    A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to Vδ1 γδ T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores αβ T cell-derived engineering strategies applicable to γδ T cells, while also highlighting genome-editing innovations poised to advance next-generation γδ CAR-T development.
    Journal
    |
    CD70 (CD70 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    7ms
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CTX131